{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:59:09Z","timestamp":1787507949412,"version":"build-2736575974"},"reference-count":61,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cholangiocarcinoma is a malignancy of the bile ducts that is often associated with late diagnosis, poor overall survival, and limited treatment options. The standard of care therapy for cholangiocarcinoma has been cytotoxic chemotherapy with modest improvements in overall survival with the addition of immune checkpoint inhibitors. The discovery of actionable mutations has led to the advent of targeted therapies against FGFR and IDH-1, which has expanded the treatment landscape for this patient population. Significant efforts have been made in the pre-clinical space to explore novel immunotherapeutic approaches, as well as antibody\u2013drug conjugates. This review provides an overview of the current landscape of treatment options, as well as promising future therapeutic targets.<\/jats:p>","DOI":"10.3390\/ijms25010543","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T06:37:12Z","timestamp":1704004632000},"page":"543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review"],"prefix":"10.3390","volume":"25","author":[{"given":"Matthew J.","family":"Hadfield","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, The Warren Alpert School of Medicine of Brown University, Providence, RI 02806, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"DeCarli","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, The Warren Alpert School of Medicine of Brown University, Providence, RI 02806, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinan","family":"Bash","sequence":"additional","affiliation":[{"name":"Department of Graduate Studies, University of New England, Biddeford, ME 04005, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, The Warren Alpert School of Medicine of Brown University, Providence, RI 02806, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaldoun","family":"Almhanna","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, The Warren Alpert School of Medicine of Brown University, Providence, RI 02806, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jso.21141","article-title":"Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)","volume":"98","author":"Duffy","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","article-title":"Evolution of surgical treatment for perihilar cholangiocarcinoma: A single-center 34-year review of 574 consecutive resections","volume":"258","author":"Nagino","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejso.2019.11.499","article-title":"Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis","volume":"46 Pt A","author":"Rangarajan","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-21-0950","article-title":"Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors","volume":"21","author":"Adashek","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma","volume":"24","author":"Sohal","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","article-title":"Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer","volume":"23","author":"Philip","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Churi, C.R., Shroff, R., Wang, Y., Rashid, A., Kang, H.C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., and Meric-Bernstam, F. (2014). Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115383"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Valle","year":"2020","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: A systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eaaz3221","DOI":"10.1126\/sciadv.aaz3221","article-title":"Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_33","first-page":"42","article-title":"Overexpression of the HER2\/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/annonc\/mdm006","article-title":"Gene amplification and protein overexpression of HER-2\/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: Its prognostic implication in node-positive patients","volume":"18","author":"Kim","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/onco.13800","article-title":"Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature","volume":"26","author":"May","year":"2021","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study","volume":"23","author":"Beeram","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: A review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/PAT.0b013e3283653307","article-title":"The analysis of microsatellite instability in extracolonic gastrointestinal malignancy","volume":"45","author":"Williams","year":"2013","journal-title":"Pathology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101157","DOI":"10.1016\/j.esmoop.2023.101157","article-title":"Lenvatinib plus pembrolizumab a new effective combination of targeted agents","volume":"8","author":"Martinelli","year":"2023","journal-title":"ESMO Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103893","DOI":"10.1016\/j.amsu.2022.103893","article-title":"A review of NTRK fusions in cancer","volume":"79","author":"Manea","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Farha, N., Dima, D., Ullah, F., and Kamath, S. (2023). Precision Oncology Targets in Biliary Tract Cancer. Cancers, 15.","DOI":"10.3390\/cancers15072105"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kuwatani, M., and Sakamoto, N. (2023). Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives. Cancers, 15.","DOI":"10.3390\/cancers15143686"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/1535-7163.MCT-21-0015","article-title":"Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma","volume":"20","author":"Yokota","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-023-00447-z","article-title":"Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma","volume":"7","author":"Zhu","year":"2023","journal-title":"NPJ Precis Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.21037\/atm.2018.07.16","article-title":"Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids","volume":"6","author":"Danese","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","article-title":"Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:44:59Z","timestamp":1760132699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010543"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010543","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,30]]}}}